Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S210000, C546S187000, C546S146000, C544S060000, C544S128000, C544S129000, C544S360000, C544S363000, C514S316000, C514S307000, C514S252010, C514S235500, C514S227800
Reexamination Certificate
active
07041681
ABSTRACT:
This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.
REFERENCES:
patent: 3023235 (1962-02-01), Frederick
patent: 3763218 (1973-10-01), Hohenlohe
patent: 4563306 (1986-01-01), Ishida et al.
patent: 2002/0161189 (2002-10-01), Lazarus et al.
patent: 0506468 (1992-09-01), None
patent: 2735776 (1996-12-01), None
patent: 5339240 (1993-12-01), None
patent: WO 96/06855 (1996-03-01), None
patent: WO 02/36116 (2002-05-01), None
Obase, H. et al: “New Antihypertensive Agents. II. Studies on New Analog of 4-Piperidylbenzimidazolinones” Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan. Tokyo, Up. vol. 630, No. 2, 1982, pp. 474-483, XP000974108.
Tripp, et al.: “Synthesis of methylene- and carbonyl-bridged analogs of iodothyronines and iodothyroacetic acids”. Journal of Medicinal Chemistry, American Chemical Society, Washington, U.S. vol. 16, No. 1, 1973, pp. 60-64, XP002113321.
Krenitsky, P.J. et al: “Preparation of the 14-membered 1,1-cyloisodityrosine subunit of RP 66453”. Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 43, No. 3, Jan. 14, 2002, pp. 407-410, XP004329390.
Leonard, F. et al: “Unnatural amino acids. II. Congeners of DL-3-carboxy-4-methoxyphenylalanine”. J. Med. Chem., vol. 10, 1967, pp. 478-481, XP00258212.
Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenscaften, Frankfurt am Main, DE: Database accession No. 5644822, XP002258213 & MAEDA, H. et al: Chem. Pharm. Bull., vol. 36, No. 1, 1988, pp. 190-201.
PCT International Search Report, PCT/US03/11872, Nov. 6, 2003.
Partial Internatioinal Search Report for PCT/US03/11872 dated Jul. 18, 2003 attached as Annex to Form PCT/ISA/206.
Gianfranco Balboni et al., “Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei”,Peptides2000, 21, pp. 1663-1671.
Gianfranco Balboni et al., “Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent δ-Opioid Receptor Antagonist into a Potent δ Agonist and Ligands with Mixed Properties”, J. Med. Chem. 2002, 45, 713-720.
Marnix, A. Hoitink et al., “Degradation of Azaglycinamido Residues in Model Tripeptides Derived from Goserelin”, Journal of Pharmaceutical Sciences, vol. 89, No. 1, Jan. 200, pp. 108-114.
Severo Salvadori et al, “Evolution of the DMt-Tic Pharmacophonre: N-Terminal Methylated Derivatives with Extraordinary δ Opioid Antagonist Activity”, J. Med. Chem. 1997, 40, 3100-3108.
D.S. Fries, “Analgesics”, inPrinciples of Medicinal Chemistry, 4th ed.; W.O. Foye, T.L. Lemke, and D.A. Williams, Eds.; Williams and Wilkins: Baltimore, Md., 1995; pp. 247-269.
J.V. Aldrich, “Analgesics”,Burger's Medicinal Chemistry and Drug Discovery, 5thEdition, vol. 3: Therapeutic Agents, John Wiley & Sons, Inc., 1996, pp. 321-441.
Pierre J.M. Riviere and Jean-Louis Junien, “Opioid receptors: Targets for new gastrointestinal drug development”, Drug Development 2000, pp. 203-238.
Brian J. Marsden, Thi M.-D. Nguyen and Peter W. Schiller, “Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroisoquinoline-3-carboxylic acid residue in the 2-position of the peptide sequence”, Int. J. pept. Protein Res. 1993, 41 (3), pp. 313-316.
Gianfranco Balboni et al., “Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei”,Peptides2000, 21, pp. 1663-1671.
Mark P. Wentland et al., “3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties”,Biorganic&Medicinal Chemistry Letters2001, 11, pp. 1717-1721.
Mark P. Wentland et al., “8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines”,Biorganic&Medicinal Chemistry Letters2001, 11, pp. 623-626.
Philip L. Gould, “Salt selection for basic drugs”, International Journal of Pharmaceutics, vol. 33, (1986) pp. 201-217.
Stephen M. Berge et al., “Pharmaceutical Salts”,Journal of Pharmacedutical Sciences, 1977 (Jan.), vol. 66, No. 1, pp. 1-19.
Tao Ye, et al., “Synthesis of Chiral N-Protected α-Amino-β-Diketones from α-Diazoketones Derived from Natural Amino Acids”,Tetrahedron1992, vol. 48, No. 38, pp. 8007-8022.
Kouichi Kikuchi et al., “Syntheses and Structure-Activity Relationships of 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-quinoxaline Derivatives with Retinoic Acid Recepton α Agonistic Activity”,J. Med. Chem. 2000, 43, pp. 409-419.
Maeda, H. et al., Synthesis and Central Nervous System Actions of Thyrotropin-Releasing Hormone Analogs Containing a 1-Oxo-1,2,3,4-tetrahydroisoquinoline Moiety1, Chem. Pharm. Bull. 36(1) 1988, 190-201.
Patent abstracts of Japan, vol. 18, No. 182, 1994, & JP 05 339240, 1993.
Breslin Henry J.
He Wei
Kavash Robert W.
Aulakh Charanjit S.
Janssen Pharmaceutica N.V.
LandOfFree
Compounds as opioid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as opioid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as opioid receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3648841